The Role of Melatonin in The Pathogenesis of Polycystic Ovary Syndrome and Its Association With Anovulation

Bakirova Asel  Stanislavovna; Maksudova Dilafruzxon  Ravshanovna

doi:10.51699/cajmns.v7i3.3304

Authors

Bakirova Asel Stanislavovna Tashkent State Medical University
Maksudova Dilafruzxon Ravshanovna Tashkent State Medical University

DOI:

https://doi.org/10.51699/cajmns.v7i3.3304

Keywords:

Melatonin, Polycystic ovary syndrome, PCOS, Hyperandrogenism, Antioxidant system

Abstract

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder characterized by hyperandrogenism, obesity, irregular menstrual cycles, and anovulatory infertility. Melatonin, the primary hormone of the pineal gland, is synthesized from tryptophan and represents an indole derivative of serotonin. Melatonin regulates not only the sleep–wake cycle but also reproductive function. It acts as a potent antioxidant that neutralizes free radicals, thereby protecting ovarian follicles during their maturation. However, when melatonin synthesis is restricted — as may occur in the context of sleep disorders — the balance of the antioxidant defense system may deteriorate, consequently impairing the normal growth and maturation of follicles in patients with PCOS, who are known to exhibit elevated levels of lipid peroxidation products that cause oocyte damage.

References

I. B. Manukhin, M. A. Gevorkyan, and E. I. Manukhina, Gynecological Endocrinology. 2024, pp. 161–162.

M. H. Asgari, M. Moloudi-Zargari, H. Bahadar, and M. Abdollahi, “A review of the protective effect of melatonin against pesticide-induced toxicity,” Expert Opinion on Drug Metabolism and Toxicology, vol. 13, no. 5, pp. 545–554, 2017.

M. H. Asgari, M. Moloudi-Zargari, E. Gobadi, M. Fallah, and M. Abdollahi, “Melatonin as a multifunctional anticancer molecule: Implications in gastric cancer,” Life Sciences, vol. 185, pp. 38–45, 2017, doi: 10.1016/j.lfs.2017.07.020.

R. J. Reiter, D. Tan, H. Tamura, M. H. Cruz, and L. Fuentes-Broto, “Clinical relevance of melatonin in ovarian and placental physiology: A review,” Gynecological Endocrinology, vol. 30, no. 2, pp. 83–89, 2013, doi: 10.3109/09513590.2013.849238.

M. T. Itoh, B. Ishizuka, Y. Kudo, et al., “Detection of melatonin and serotonin N-acetyltransferase and hydroxyindole-O-methyltransferase activities in rat ovary,” Molecular and Cellular Endocrinology, vol. 136, no. 1, pp. 7–13, 1997.

I. I. Dedov, G. A. Mel’nichenko, and V. V. Fadeev, Endocrinology. 2015, p. 199.

C. R. McCartney, C. A. Eagleson, and J. C. Marshall, “Regulation of gonadotropin secretion: Implications for polycystic ovary syndrome,” Seminars in Reproductive Medicine, vol. 20, no. 4, pp. 317–325, 2002.

M. H. Cruz, C. L. Leal, J. F. Cruz, et al., “Essential actions of melatonin in protecting the ovary from oxidative damage,” Theriogenology, vol. 82, no. 7, pp. 925–932, 2014.

C. J. Bailey, T. W. Atkins, and A. J. Matty, “Melatonin inhibition of insulin secretion in the rat and mouse,” Hormone Research, vol. 5, no. 1, pp. 21–28, 1974.

C. J. McMullan, E. S. Schernhammer, E. B. Rimm, F. B. Hu, and J. P. Forman, “Melatonin secretion and the incidence of type 2 diabetes,” JAMA, vol. 309, pp. 1388–1396, 2013.

R. Genario, J. Cipolla-Neto, A. A. Bueno, and H. O. Santos, “Melatonin supplementation in the management of obesity and obesity-associated disorders: A review of physiological mechanisms and clinical applications,” Pharmacological Research, vol. 163, p. 105254, 2021.

V. Tagliaferri, D. Romualdi, E. Scarinci, et al., “Melatonin treatment may be able to restore menstrual cyclicity in women with PCOS: A pilot study,” Reproductive Sciences, vol. 25, no. 2, pp. 269–275, 2018.

P. Lokhrasbi, S. Karbalaei-Doust, S. M. B. Tabei, N. Azarpira, S. Alai, B. Rafiei, et al., “Effect of melatonin and metformin on histological characteristics of the ovaries and uterus in letrozole-induced polycystic ovary syndrome mice: A stereological study,” International Journal of Reproductive BioMedicine, vol. 20, pp. 973–988, 2022.

S. A. Pai and A. S. Majumdar, “Protective effects of melatonin against metabolic and reproductive disturbances in polycystic ovary syndrome in rats,” Journal of Pharmacy and Pharmacology, vol. 66, no. 12, pp. 1710–1721, 2014.

A. J. J. M. de Lemos-Jordão, F. S. Costa, C. A. Peixoto, A. A. C. Teixeira, S. B. da Silva, C. G. M. Ferreira, et al., “Combination of melatonin and metformin hydrochloride for treatment of polycystic ovaries in female rats,” Acta Scientiae Veterinariae, vol. 44, p. 10, 2016.